Today: 28 June 2026
Browse Category

Biotechnology 22 June 2025 - 16 August 2025

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Wegovy became the first GLP-1 therapy approved by the FDA for MASH, affecting about 5% of U.S. adults. Tonix’s Tonmya was cleared for fibromyalgia, the first new therapy in 15 years. Pfizer’s inclacumab failed a key sickle cell trial, and Oxbryta was withdrawn. BioNTech agreed to acquire CureVac in a $1.25 billion all-stock deal.
16 August 2025
··········
Biotech & Health Bombshells: FDA Greenlights, Clinical Breakthroughs & Global Health Milestones (Aug 8–9, 2025)

Biotech & Health Bombshells: FDA Greenlights, Clinical Breakthroughs & Global Health Milestones (Aug 8–9, 2025)

The FDA approved Boehringer Ingelheim’s lung cancer drug Hernexeos and a companion diagnostic on Aug 8, citing trial data showing tumor shrinkage in 75% of eligible patients. The agency restricted Bluebird Bio’s Skysona gene therapy to patients lacking a matched donor due to blood cancer risk. Stealth BioTherapeutics’ Barth syndrome drug was rejected for a third time. The FDA declared the U.S. IV saline shortage over.
9 August 2025
··
Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

The FDA approved Abeona’s Zevaskyn, the first cell-based gene therapy for RDEB, in April 2025, with launch set for Q3 at $3.1 million. Vertex’s CRISPR therapy Casgevy generated $2 million in Q3 2024. Novo Holdings acquired Catalent for $16.5 billion in January 2025 to secure GLP-1 drug manufacturing. Johnson & Johnson bought Intra-Cellular Therapies for $14.6 billion, expanding its neuroscience portfolio.
27 June 2025
···········
Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Pfizer and BioNTech co-developed Comirnaty, the first FDA-approved mRNA COVID-19 vaccine. Roche leads in oncology and diagnostics, while Moderna advanced mRNA vaccines for COVID-19 and other diseases. Illumina dominates DNA sequencing, and CRISPR Therapeutics develops gene-editing therapies for sickle cell disease.
22 June 2025
···········
1 … 17 18 19

Stock Market Today

  • Dodla Dairy Earnings Highlight Profit Boost from Unusual Items
    June 28, 2026, 12:01 AM EDT. Dodla Dairy Limited's latest earnings reveal a ₹246 million boost from unusual items, raising concerns about the sustainability of profit growth. Despite strong earnings per share growth over three years, the one-off nature of these gains suggests potential profit declines if such contributions do not recur. Analysts emphasize caution interpreting statutory profits as a true reflection of ongoing business performance. Investors should consider underlying risks flagged by market data and examine broader financial metrics such as return on equity and insider holdings. The mixed signals have kept the stock price largely unchanged, indicating market apprehension about earnings quality and future profitability.

Latest articles

Hecla Mining (NYSE:HL) sees stock rebound, volume jumps as silver prices in focus

Hecla Mining (NYSE:HL) sees stock rebound, volume jumps as silver prices in focus

28 June 2026
Hecla Mining surged 5.3 times its average trading volume Friday as index rebalancing drove 112.44 million shares traded, but the stock’s 2.6% weekly drop still beat silver and peer ETFs, signaling company-specific strength; investors now watch if Hecla can hold above $15.54 without rebalancing flows as macro risks loom.
Go toTop